Save the New Tetracycline Omadacycline (Nuzyra) as a Last Resort

January 2019

You'll see a new, once-daily, IV and PO tetracycline antibiotic, omadacycline (Nuzyra, noo-ZYE-rah).

It's approved for community-acquired pneumonia (CAP)...or skin infections, including methicillin-resistant Staph aureus (MRSA).

Evidence suggests omadacycline is non-inferior to moxifloxacin for CAP or linezolid for skin infections. And omadacycline costs about $350/IV dose or $400/oral dose.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote